SONN News and Press, Sonnet BioTherapeutics Holdings Inc. From 09/20/23

2023-09-20 09:21:37 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Sonnet BioTherapeutics stock plummets 20% ...

Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mIL12-F H AB, the mouse version of SON‑1010, compared with mIL-12 alone Accumulation was observed in tumors compared to normal mice, and was expectedly transient in liver and kidney The ...

2023-09-19 09:38:06 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Sonnet BioTherapeutics stock plummets 20% ...

PRINCETON, NJ / ACCESSWIRE / September 19, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market indicat...

2023-08-31 13:34:16 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Earnings data for Sonnet BioTherapeutics For further details see: Sonnet BioTherapeutics launches 1-for-22 reverse stock split

PRINCETON, NJ / ACCESSWIRE / August 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-22 reverse stock split of its outstanding common ...

2023-08-25 07:20:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product. But there are also plenty of pitfalls that make such...

An IND was required to conduct the SB221 study of platinum-resistant ovarian cancer (PROC) with the combination of Sonnet's SON-1010 and Roche's atezolizumab (Tecentriq ® ) in the US As part of the overall design of the program, the clinical trial was initiated at several sites in A...

2023-08-14 09:03:51 ET Sonnet BioTherapeutics press release ( NASDAQ: SONN ): Q3 GAAP EPS of -$0.13. Revenue of $36.85M (-40.6% Y/Y). For further details see: Sonnet BioTherapeutics GAAP EPS of -$0.13, revenue of $36.85M

Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in Australia First SON-1010 Phase 1 study has been completed and comparison of the human pharmacokinetic data supports targeting of tumor tissue Early safety data from the SON-080 trial in CIPN ...